Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Phase 3CompletedDevelopment Stage
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Oct 1, 2012 → Aug 1, 2014
About Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Ceftazidime - Avibactam ( CAZ-AVI) + Doripenem + Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) + or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral) is a phase 3 stage product being developed by Pfizer for Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01599806. Target conditions include Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis.
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01595438 | Phase 3 | Completed |
| NCT01599806 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis